Home Voor zorgverleners Werkgroep Sjögren

Werkgroep Sjögren

Op deze pagina kunt u meer lezen over de activiteiten van de werkgroep Sjögren. Hier staat wat de werkgroep precies is, welke centra zijn aangesloten bij de werkgroep, publicaties waar meerdere aangesloten centra bij betrokken zijn geweest, opgestelde consensusdocumenten, informatie over lopend onderzoek, en ten slotte het werkplan voor het huidige jaar.

Introductie
Wie zijn wij?
Lopend Onderzoek
Consensusdocumenten
Publicaties
Spreekkamerkaarten

Introductie

Naast expertiseconsulten voor directe zorgverlening is ARCH ook betrokken bij onderzoek om de zorg voor patiënten met een systemische auto-immuunziekte te verbeteren. Er is een landelijke multidisciplinaire werkgroep voor Sjögren. De werkgroep vergadert vier keer per jaar om elkaar te informeren, te brainstormen en af te stemmen over gezamenlijke registratie van klinische kerngegevens, wetenschappelijk onderzoek- en zorgprojecten, en over ontwikkelingen nationaal en internationaal. In deze werkgroep zitten naast zorgverleners ook patiëntvertegenwoordigers. De deelname van patiëntvertegenwoordigers loopt via de Nationale Vereniging Sjögrenpatiënten (NVSP). Wilt u zich aanmelden? Dat kan! Mail naar info@arch.nl of neem contact op met een van uw collega’s uit de deelnemende centra.

Wie zijn wij?

Zana Brkic (Voorzitter), internist-allergoloog/klinisch immunoloog (Erasmus MC), (Voorzitter.WG.Sjogren@arch.nl)

Sofie Blokland (Secretaris), arts reumatologie (UMCU), (Secretaris.WG.Sjogren@arch.nl)

 

De leden van de werkgroep bestaan uit vertegenwoordigers vanuit verschillende organisaties: NVSP, Amsterdam UMC, Erasmus MC, Franciscus Gasthuis, Haga Ziekenhuis, Jeroen Bosch Ziekenhuis, Meander Medisch Centrum, Maastricht UMC, OVLG, Radboud UMC, Reumazorg Friesland/Flevoland, UMC Groningen, UMC Utrecht en Sint Maartenskliniek.

Lopend Onderzoek

Leden van de werkgroep coördineren en nemen deel aan verschillende onderzoeken:

  • ANISE-II: anifrolumab (anti-IFNAR), UMC Groningen (expertisecentrum-sjogren@umcg.nl).
  • TWINNS: iscalimab (anti-CD40), UMC Groningen en Erasmus MC (inclusie gesloten)
  • Dahlias: nipocalimab (anti-FcRn), Erasmus MC (inclusie gesloten)
  • Necessity: combinatietherapie MMF en hydroxychloroquine, leflunomide en hydroxychloroquine, UMC Groningen en UMC Utrecht

Consensusdocumenten

Met samenwerking van medisch experts, zijn er meerdere gezamenlijke standpunten/ consensusdocumenten opgesteld over Sjögren. Hieronder staan deze consensusdocumenten benoemd. Deze standpunten zijn niet direct opgesteld door ARCH. Dit zijn documenten waar vertegenwoordigers uit meerdere centra betrokken bij de werkgroep aan mee hebben gewerkt.

 

Publicaties

Publicaties over Sjögren waar meerdere leden van de de ARCH WG Sjögren (co-)auteur van zijn (afgelopen 5 jaar):

  1. Extranodal marginal zone lymphoma clonotypes are detectable prior to eMZL diagnosis in tissue biopsies and peripheral blood of Sjögren’s syndrome patients through immunogenetics.
    Kolijn PM, Huijser E, Wahadat MJ, van Helden-Meeuwsen CG, van Daele PLA, Brkic Z, Rijntjes J, Hebeda KM, Groenen PJTA, Versnel MA, Thurlings RM, Langerak AW.Front Oncol. 2023 Mar 23;13:1130686. doi: 10.3389/fonc.2023.1130686. eCollection 2023.PMID: 37035202
  2. Added value of the salivary gland ultrasonography OMERACT score in the ACR/EULAR classification criteria for Sjögren’s disease. Rebel D, de Wolff L, Delli K, Stel AJ, Kokol HC, Vissink A, Kroese FGM, Arends S, Bootsma H.Semin Arthritis Rheum. 2024 Aug;67:152473. doi: 10.1016/j.semarthrit.2024.152473. Epub 2024 May 21.PMID: 38805898
  3. Increased Interferon Signaling in Vaginal Tissue of Patients With Primary Sjögren Syndrome. Visser A, van Nimwegen JF, Wilbrink R, Liefers SC, van der Tuuk K, Mourits MJE, Diercks GFH, Bart J, van der Vegt B, van Kempen LC, Bootsma H, Kroese FGM, Verstappen GM.J Rheumatol. 2024 Jul 1;51(7):687-695. doi: 10.3899/jrheum.2023-1068.PMID: 38561184
  4. Subgroups of Sjögren’s disease: are they of any help?Arends S, Vissink A, Bootsma H.Lancet Rheumatol. 2024 Apr;6(4):e191-e193. doi: 10.1016/S2665-9913(24)00029-8. Epub 2024 Mar 1.PMID: 38437853
  5. The Sjögren’s Working Group: The 2023 OMERACT meeting and provisional domain generation. Gordon RA, Nguyen Y, Foulquier N, Beydon M, Gheita TA, Hajji R, Sahbudin I, Hoi A, Ng WF, Mendonça JA, Wallace DJ, Shea B, Bruyn GA, Goodman SM, Fisher BA, Baldini C, Torralba KD, Bootsma H, Akpek EK, Karakus S, Baer AN, Chakravarty SD, Terslev L, D’Agostino MA, Mariette X, DiRenzo D, Rasmussen A, Papas A, Montoya C, Arends S, Yusof MYM, Pintilie I, Warner BM, Hammitt KM, Strand V, Bouillot C, Tugwell P, Inanc N, Andreu JL, Wahren-Herlenius M, Devauchelle-Pensec V, Shiboski CH, Benyoussef A, Masli S, Lee AYS, Cornec D, Bowman S, Rischmueller M, McCoy SS, Seror R.Semin Arthritis Rheum. 2024 Apr;65:152378. doi: 10.1016/j.semarthrit.2024.152378. Epub 2024 Jan 23.PMID: 38310657
  6. Longitudinal evaluation of major salivary gland functioning in Sjögren’s disease patients in a prospective standard-of-care cohort. Sluijpers NRF, Delli K, De Wolff L, Stel AJ, Spijkervet FKL, Kroese FGM, Bootsma H, Arends S, Vissink A.Clin Exp Rheumatol. 2023 Dec;41(12):2474-2483. doi: 10.55563/clinexprheumatol/cjxd4i. Epub 2023 Dec 26.PMID: 38149509
  7. Can ultrasound of the major salivary glands differentiate Sjögren’s disease from its major mimics? Delli K, Van Nimwegen JF, Arends S, Stel AJ, Gan CT, Bierman WFW, Spijkervet FKL, Bootsma H, Vissink A.Clin Exp Rheumatol. 2023 Dec;41(12):2467-2473. doi: 10.55563/clinexprheumatol/32arho. Epub 2023 Dec 11.PMID: 38079345
  8. Salivary gland 18F-FDG-PET/CT uptake patterns in Sjögren’s syndrome and giant cell arteritis patients. Grootelaar RGJ, van Ginkel MS, Nienhuis PH, Arends S, Pieterman RM, Brouwer E, Bootsma H, Glaudemans AWJM, Slart RHJA.Clin Exp Rheumatol. 2023 Dec;41(12):2428-2436. doi: 10.55563/clinexprheumatol/8qt9me. Epub 2023 Dec 5.PMID: 38079331
  9. Serum and Tissue Biomarkers Associated With Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B Cell-Targeted Therapy in the Trial of Anti-B Cell Therapy in Patients With Primary Sjögren Syndrome (TRACTISS). bPontarini E, Sciacca E, Chowdhury F, Grigoriadou S, Rivellese F, Murray-Brown WJ, Lucchesi D, Fossati-Jimack L, Nerviani A, Jaworska E, Ghirardi GM, Giacomassi C, Emery P, Ng WF, Sutcliffe N, Everett C, Fernandez C, Tappuni A, Seror R, Mariette X, Porcher R, Cavallaro G, Pulvirenti A, Verstappen GM, de Wolff L, Arends S, Bootsma H, Lewis MJ, Pitzalis C, Bowman SJ, Bombardieri M; Trial for Anti–B Cell Therapy in Patients With Primary Sjögren Syndrome Study Research Group.Arthritis Rheumatol. 2024 May;76(5):763-776. doi: 10.1002/art.42772. Epub 2024 Feb 15.PMID: 38073013 Clinical Trial.
  10. Increased Diagnostic Accuracy of the Labial Gland Biopsy in Primary Sjögren Syndrome When Multiple Histopathological Features Are Included. van Ginkel MS, Nakshbandi U, Arends S, Haacke EA, Liefers SC, Verstappen GM, van Nimwegen JF, Brouwer E, Stel AJ, Spijkervet FKL, Vissink A, Bootsma H, van der Vegt B, Kroese FGM.Arthritis Rheumatol. 2024 Mar;76(3):421-428. doi: 10.1002/art.42723. Epub 2024 Jan 9.PMID: 37791984
  11. Preconception clinical factors related to adverse pregnancy outcomes in patients with systemic lupus erythematosus or primary Sjögren’s syndrome: a retrospective cohort study. Fierro JJ, Prins JR, Verstappen GM, Bootsma H, Westra J, de Leeuw K.RMD Open. 2023 Aug;9(3):e003439. doi: 10.1136/rmdopen-2023-003439.PMID: 37652559
  12. Minimal added value of separate dryness assessments compared with overall dryness in ESSPRI in patients with Sjögren’s disease. de Wolff L, Arends S, Verstappen GM, Bootsma H.Rheumatology (Oxford). 2024 Feb 1;63(2):e29-e31. doi: 10.1093/rheumatology/kead441.PMID: 37632773
  13. CCR9/CXCR5 Co-Expressing CD4 T Cells Are Increased in Primary Sjogren’s Syndrome and Are Enriched in PD-1/ICOS-Expressing Effector T Cells. Hinrichs AC, Kruize AA, Lafeber FPJG, Leavis HL, van Roon JAG.Int J Mol Sci. 2023 Jul 26;24(15):11952. doi: 10.3390/ijms241511952.PMID: 37569326
  14. Why do drug treatments fail in Sjögren’s disease? Considerations for treatment, trial design and interpretation of clinical efficacy. Arends S, Verstappen GM, de Wolff L, Pringle S, Kroese FGM, Vissink A, Bootsma H.Expert Rev Clin Immunol. 2023 Jul-Dec;19(10):1187-1194. doi: 10.1080/1744666X.2023.2234641. Epub 2023 Aug 8.PMID: 37551702 Review.
  15. Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren’s syndrome that show potential to predict and monitor clinical response. Hamkour S, van der Heijden EH, Lopes AP, Blokland SLM, Bekker CPJ, Van Helden-Meeuwsen CG, Versnel MA, Kruize AA, Radstake TR, Leavis HL, Hillen MR, van Roon JA.RMD Open. 2023 Aug;9(3):e002979. doi: 10.1136/rmdopen-2023-002979.PMID: 37532471
  16. A leading role for interferon as a treatment target in Sjögren syndrome. Verstappen GM, Kroese FGM.Nat Rev Rheumatol. 2023 Aug;19(8):468-469. doi: 10.1038/s41584-023-00991-9.PMID: 37322372
  17. Targeting plasma cells in systemic autoimmune rheumatic diseases – Promises and pitfalls. Steinmetz TD, Verstappen GM, Suurmond J, Kroese FGM.Immunol Lett. 2023 Aug;260:44-57. doi: 10.1016/j.imlet.2023.06.005. Epub 2023 Jun 12.PMID: 37315847
  18. FDG-PET/CT discriminates between patients with and without lymphomas in primary Sjögren’s syndrome. van Ginkel MS, Arends S, van der Vegt B, Nijland M, Spijkervet FKL, Vissink A, Kroese FGM, Glaudemans AWJM, Bootsma H.Rheumatology (Oxford). 2023 Oct 3;62(10):3323-3331. doi: 10.1093/rheumatology/kead071.PMID: 36759907
  19. Association of Circulating Antibody-Secreting Cell Maturity With Disease Features in Primary Sjögren’s Syndrome. Steinmetz TD, Verstappen GM, Schulz SR, de Wolff L, Wilbrink R, Visser A, Terpstra J, Bootsma H, Kroese FGM.Arthritis Rheumatol. 2023 Jun;75(6):973-983. doi: 10.1002/art.42422. Epub 2023 Mar 22.PMID: 36533856
  20. In patients with primary Sjögren’s syndrome innate-like MAIT cells display upregulated IL-7R, IFN-γ, and IL-21 expression and have increased proportions of CCR9 and CXCR5-expressing cells. Hinrichs AC, Kruize AA, Leavis HL, van Roon JAG.Front Immunol. 2022 Nov 24;13:1017157. doi: 10.3389/fimmu.2022.1017157. eCollection 2022.PMID: 36505431
  21. A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome. Mariette X, Barone F, Baldini C, Bootsma H, Clark KL, De Vita S, Gardner DH, Henderson RB, Herdman M, Lerang K, Mistry P, Punwaney R, Seror R, Stone J, van Daele P, van Maurik A, Wisniacki N, Roth DA, Tak PP.JCI Insight. 2022 Dec 8;7(23):e163030. doi: 10.1172/jci.insight.163030.PMID: 36477362  Clinical Trial.
  22. Patient Acceptable Symptom State (PASS) in patients with primary Sjögren’s syndrome in daily clinical practice. de Wolff L, Vissink A, van Nimwegen JF, van Zuiden G, Mossel E, Olie L, Stel AJ, Delli K, Verstappen GM, Kroese FGM, Bootsma H, Arends S.Clin Exp Rheumatol. 2022 Dec;40(12):2303-2309. doi: 10.55563/clinexprheumatol/mnqiy9. Epub 2022 Nov 28.PMID: 36441658
  23. Safety and efficacy of SARS-CoV-2 vaccination in 1237 patients with primary Sjögren syndrome. Inanc N, Kostov B, Priori R, Flores-Chavez A, Carubbi F, Szántó A, Valim V, Bootsma H, Praprotnik S, Fernandes Moça Trevisani V, Hernández-Molina G, Hofauer B, Pasoto SG, López-Dupla M, Bartoloni E, Rischmueller M, Devauchelle-Pensec V, Abacar K, Giardina F, Alunno A, Fanny Horváth I, de Wolff L, Caldas L, Retamozo S, Ramos-Casals M, Brito-Zerón P; Sjögren Big Data Consortium.Clin Exp Rheumatol. 2022 Dec;40(12):2290-2297. doi: 10.55563/clinexprheumatol/dt6klo. Epub 2022 Nov 17.PMID: 36441656
  24. Selection of study endpoints and patients for clinical trials in primary Sjögren’s syndrome. Arends S, de Wolff L, Deroo L, Verstappen GM, Vissink A, Kroese FGM, Elewaut D, Peene I, Bootsma H.Clin Exp Rheumatol. 2022 Dec;40(12):2225-2232. doi: 10.55563/clinexprheumatol/yagocb. Epub 2022 Oct 26.PMID: 36305355
  25. Can salivary gland ultrasonography replace salivary gland biopsy in the diagnosis of Sjögren’s syndrome? Delli K, van Ginkel MS, Vissink A, Stel AJ, van der Vegt B, Spijkervet FKL, Kroese FGM, Arends S, Bootsma H.Clin Exp Rheumatol. 2022 Dec;40(12):2443-2449. doi: 10.55563/clinexprheumatol/xbcu8d. Epub 2022 Oct 25.PMID: 36305349  Review.
  26. Fatigue in primary Sjögren’s syndrome is associated with an objective decline in physical performance, pain and depression. Prak RF, Arends S, Verstappen GM, van Zuiden G, Kroese FGM, Bootsma H, Zijdewind I.Clin Exp Rheumatol. 2022 Dec;40(12):2318-2328. doi: 10.55563/clinexprheumatol/70s6cs. Epub 2022 Oct 12.PMID: 36226629
  27. Lymphoepithelial lesions in the salivary glands of primary Sjögren’s syndrome patients: the perfect storm? Pringle S, Verstappen GM, van Ginkel MS, Nakshbandi U, Girigoria Z, Bootsma H, van der Vegt B, Kroese FGM.Clin Exp Rheumatol. 2022 Dec;40(12):2434-2442. doi: 10.55563/clinexprheumatol/06an99. Epub 2022 Oct 12.PMID: 36226606  Review.
  28. Deciphering the role of cDC2s in Sjögren’s syndrome: transcriptomic profile links altered antigen processes with IFN signature and autoimmunity. Lopes AP, Hillen MR, Hinrichs AC, Blokland SL, Bekker CP, Pandit A, Kruize AA, Radstake TR, van Roon JA.Ann Rheum Dis. 2023 Mar;82(3):374-383. doi: 10.1136/ard-2022-222728. Epub 2022 Sep 28.PMID: 36171070
  29. Immunisation with Coronavirus-2 vaccines induces potent antibody responses and does not aggravate the lymphocyte compartment of primary Sjögren’s syndrome patients. Steinmetz TD, de Wolff L, Terpstra JH, Visser A, Bootsma H, Kroese FGM, Verstappen GM.Clin Exp Rheumatol. 2022 Dec;40(12):2338-2343. doi: 10.55563/clinexprheumatol/1iaqnu. Epub 2022 Sep 5.PMID: 36063118
  30. Trained Immunity in Primary Sjögren’s Syndrome: Linking Type I Interferons to a Pro-Atherogenic Phenotype. Huijser E, van Helden-Meeuwsen CG, Grashof DGB, Tarn JR, Brkic Z, Huisman JMA, Wahadat MJ, van de Werken HJG, Lopes AP, van Roon JAG, van Daele PLA, Kamphuis S, Ng WF, Bekkering S, Joosten LAB, Dik WA, Versnel MA.Front Immunol. 2022 Jul 4;13:840751. doi: 10.3389/fimmu.2022.840751. eCollection 2022.PMID: 35860283
  31.  CCL5 Release by CCR9+ CD8 T Cells: A Potential Contributor to Immunopathology of Primary Sjogren’s Syndrome. Hinrichs AC, Blokland SLM, Kruize AA, Lafeber FPJ, Leavis HL, van Roon JAG.Front Immunol. 2022 Jun 1;13:887972. doi: 10.3389/fimmu.2022.887972. eCollection 2022.PMID: 35720379
  32. Decreased BAFF Receptor Expression and Unaltered B Cell Receptor Signaling in Circulating B Cells from Primary Sjögren’s Syndrome Patients at Diagnosis. Neys SFH, Verstappen GM, Bootsma H, Kroese FGM, Hendriks RW, Corneth OBJ.Int J Mol Sci. 2022 May 4;23(9):5101. doi: 10.3390/ijms23095101.PMID: 35563492
  33. Persistent low complement levels and increased interferon gene expression are predictive for disease progression in patients with incomplete systemic lupus erythematosus. Lambers WM, Westra J, Arends S, Doornbos-van der Meer B, Horvath B, Bootsma H, de Leeuw K.Joint Bone Spine. 2022 Oct;89(5):105381. doi: 10.1016/j.jbspin.2022.105381. Epub 2022 Apr 29.PMID: 35500799
  34. Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren’s syndrome. Verstappen GM, de Wolff L, Arends S, Heiermann HM, van Sleen Y, Visser A, Terpstra JH, Diavatopoulos DA, van der Heiden M, Vissink A, van Baarle D, Kroese FGM, Bootsma H.RMD Open. 2022 Apr;8(1):e002265. doi: 10.1136/rmdopen-2022-002265.PMID: 35414631
  35. Digital image analysis of intraepithelial B-lymphocytes to assess lymphoepithelial lesions in salivary glands of Sjögren’s syndrome patients. van Ginkel MS, van der Sluis T, Bulthuis MLC, Buikema HJ, Haacke EA, Arends S, Harder S, Spijkervet FKL, Bootsma H, Vissink A, Kroese FGM, van der Vegt B.Rheumatology (Oxford). 2022 Dec 23;62(1):428-438. doi: 10.1093/rheumatology/keac212.PMID: 35412585
  36. Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome. Seror R, Baron G, Camus M, Cornec D, Perrodeau E, Bowman SJ, Bombardieri M, Bootsma H, Gottenberg JE, Fisher B, Hueber W, van Roon JA, Devauchelle-Pensec V, Gergely P, Mariette X, Porcher R; NECESSITY WP5 – STAR development working group; NECESSITY WP5- STAR development working group.Ann Rheum Dis. 2022 Jul;81(7):979-989. doi: 10.1136/annrheumdis-2021-222054. Epub 2022 Apr 7.PMID: 35393271
  37. Long-term abatacept treatment for 48 weeks in patients with primary Sjögren’s syndrome: The open-label extension phase of the ASAP-III trial. de Wolff L, van Nimwegen JF, Mossel E, van Zuiden GS, Stel AJ, Majoor KI, Olie L, Los LI, Vissink A, Spijkervet FKL, Verstappen GMPJ, Kroese FGM, Arends S, Bootsma H.Semin Arthritis Rheum. 2022 Apr;53:151955. doi: 10.1016/j.semarthrit.2022.151955. Epub 2022 Jan 10.PMID: 35091325  Clinical Trial.
  38. Hyperresponsive cytosolic DNA-sensing pathway in monocytes from primary Sjögren’s syndrome. Huijser E, Bodewes ILA, Lourens MS, van Helden-Meeuwsen CG, van den Bosch TPP, Grashof DGB, van de Werken HJG, Lopes AP, van Roon JAG, van Daele PLA, Brkic Z, Dik WA, Versnel MA.Rheumatology (Oxford). 2022 Aug 3;61(8):3491-3496. doi: 10.1093/rheumatology/keac016.PMID: 35022662
  39. Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. Retamozo S, Acar-Denizli N, Horváth IF, Ng WF, Rasmussen A, Dong X, Li X, Baldini C, Olsson P, Priori R, Seror R, Gottenberg JE, Kruize AA, Hernandez-Molina G, Vissink A, Sandhya P, Armagan B, Quartuccio L, Sebastian A, Praprotnik S, Bartoloni E, Kwok SK, Kvarnstrom M, Rischmueller M, Soláns-Laqué R, Sene D, Pasoto SG, Suzuki Y, Isenberg DA, Valim V, Nordmark G, Nakamura H, Fernandes Moça Trevisani V, Hofauer B, Sisó-Almirall A, Giacomelli R, Devauchelle-Pensec V, Bombardieri M, Atzeni F, Hammenfors D, Maure B, Carsons SE, Gheita T, Sánchez-Berná I, López-Dupla M, Morel J, Inanç N, Fonseca-Aizpuru E, Morcillo C, Vollenweider C, Melchor S, Vázquez M, Díaz-Cuiza E, Consani-Fernández S, de-Miguel-Campo B, Szántó A, Bombardieri S, Gattamelata A, Hinrichs A, Sánchez-Guerrero J, Danda D, Kilic L, De Vita S, Wiland P, Gerli R, Park SH, Wahren-Herlenius M, Bootsma H, Mariette X, Ramos-Casals M, Brito-Zerón P; Sjögren Big Data Consortium.Clin Exp Rheumatol. 2021 Nov-Dec;39 Suppl 133(6):166-174. doi: 10.55563/clinexprheumatol/egnd1i. Epub 2021 Dec 16.PMID: 34919044
  40. Differences in presentation between paediatric- and adult-onset primary Sjögren’s syndrome patients. Legger GE, Erdtsieck MB, de Wolff L, Stel AJ, Los LI, Verstappen GM, Spijkervet FKL, Vissink A, van der Vegt B, Kroese FGM, Armbrust W, Arends S, Bootsma H.Clin Exp Rheumatol. 2021 Nov-Dec;39 Suppl 133(6):85-92. doi: 10.55563/clinexprheumatol/vxe6h0. Epub 2021 Nov 10.PMID: 34796855
  41. Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjögren’s syndrome. de Wolff L, Arends S, Pontarini E, Bombardieri M, Bowman SJ, Bootsma H.Clin Exp Rheumatol. 2021 Nov-Dec;39 Suppl 133(6):100-106. doi: 10.55563/clinexprheumatol/i8g5nd. Epub 2021 Nov 10.PMID: 34796851  Clinical Trial.
  42. Histopathology, salivary flow and ultrasonography of the parotid gland: three complementary measurements in primary Sjögren’s syndrome.Mossel E, van Ginkel MS, Haacke EA, Arends S, Liefers SC, Delli K, van Nimwegen JF, Stel AJ, Spijkervet FKL, Vissink A, van der Vegt B, Kroese FGM, Bootsma H.Rheumatology (Oxford). 2022 May 30;61(6):2472-2482. doi: 10.1093/rheumatology/keab781.PMID: 34672336
  43. Clinical determinants of vaginal dryness in patients with primary Sjögren’s syndrome. Farenhorst CA, de Wolff L, Arends S, van Nimwegen JF, Kroese FGM, Verstappen GM, Bootsma H.Clin Exp Rheumatol. 2021 Nov-Dec;39 Suppl 133(6):73-79. doi: 10.55563/clinexprheumatol/hzveng. Epub 2021 Oct 7.PMID: 34665706
  44. Parotid salivary sodium levels of Sjögren’s syndrome patients suggest B-cell mediated epithelial sodium channel disruption. Pringle SA, Berkhof B, van Ginkel M, Liefers S, van der Vegt B, Spijkervet FKL, Bootsma H, Vissink A, Kroese FGM.Clin Exp Rheumatol. 2021 Nov-Dec;39 Suppl 133(6):30-38. doi: 10.55563/clinexprheumatol/h9hivf. Epub 2021 Oct 14.PMID: 34665704
  45. Undernutrition and sarcopenic obesity: underrecognised conditions in patients with Sjögren’s syndrome? Jager-Wittenaar H, Vissink A, Kroese FGM, Bootsma H.Clin Exp Rheumatol. 2021 Nov-Dec;39 Suppl 133(6):20-22. doi: 10.55563/clinexprheumatol/9tnksi. Epub 2021 Sep 29.PMID: 34596029
  46. Serum interferon-α2 measured by single-molecule array associates with systemic disease manifestations in Sjögren’s syndrome. Huijser E, Göpfert J, Brkic Z, van Helden-Meeuwsen CG, Jansen S, Mandl T, Olsson P, Schrijver B, Schreurs MWJ, van Daele PLA, Dik WA, Versnel MA.Rheumatology (Oxford). 2022 May 5;61(5):2156-2166. doi: 10.1093/rheumatology/keab688.PMID: 34505866
  47. The Transcriptomic Profile of Monocytes from Patients With Sjögren’s Syndrome Is Associated With Inflammatory Parameters and Is Mimicked by Circulating Mediators. Lopes AP, Bekker CPJ, Hillen MR, Blokland SLM, Hinrichs AC, Pandit A, Kruize AA, Radstake TRDJ, van Roon JAG.Front Immunol. 2021 Aug 3;12:701656. doi: 10.3389/fimmu.2021.701656. eCollection 2021.PMID: 34413853
  48. Transcriptome Analysis of CCR9+ T Helper Cells From Primary Sjogren’s Syndrome Patients Identifies CCL5 as a Novel Effector Molecule. Hinrichs AC, Blokland SLM, Lopes AP, Wichers CGK, Kruize AA, Pandit A, Radstake TRDJ, van Roon JAG.Front Immunol. 2021 Jul 27;12:702733. doi: 10.3389/fimmu.2021.702733. eCollection 2021.PMID: 34386009
  49. The Transcriptome of Paired Major and Minor Salivary Gland Tissue in Patients With Primary Sjögren’s Syndrome. Verstappen GM, Gao L, Pringle S, Haacke EA, van der Vegt B, Liefers SC, Patel V, Hu Y, Mukherjee S, Carman J, Menard LC, Spijkervet FKL, Vissink A, Bootsma H, Kroese FGM.Front Immunol. 2021 Jul 6;12:681941. doi: 10.3389/fimmu.2021.681941. eCollection 2021.PMID: 34295332
  50. CD27–CD38lowCD21low B-Cells Are Increased in Axial Spondyloarthritis. Wilbrink R, Spoorenberg A, Arends S, van der Geest KSM, Brouwer E, Bootsma H, Kroese FGM, Verstappen GM.Front Immunol. 2021 Jun 8;12:686273. doi: 10.3389/fimmu.2021.686273. eCollection 2021.PMID: 34168654
  51. Epithelial-immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis. Verstappen GM, Pringle S, Bootsma H, Kroese FGM.Nat Rev Rheumatol. 2021 Jun;17(6):333-348. doi: 10.1038/s41584-021-00605-2. Epub 2021 Apr 28.PMID: 33911236  Review.
  52. Correspondence on ‘Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised controlled trial’. de Wolff L, Arends S, Verstappen GM, Vissink A, Kroese FGM, Bootsma H.Ann Rheum Dis. 2023 Jun;82(6):e148. doi: 10.1136/annrheumdis-2021-220198. Epub 2021 Mar 23.PMID: 33757967
  53. Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren’s Syndrome. Retamozo S, Baldini C, Bootsma H, De Vita S, Dörner T, Fisher BA, Gottenberg JE, Hernández-Molina G, Kocher A, Kostov B, Kruize AA, Mandl T, Ng WF, Seror R, Shoenfeld Y, Sisó-Almirall A, Tzioufas AG, Vissink A, Vitali C, Bowman SJ, Mariette X, Ramos-Casals M, Brito-Zerón P.Drugs Aging. 2021 Apr;38(4):265-284. doi: 10.1007/s40266-021-00838-6. Epub 2021 Feb 23.PMID: 33619703 Review.
  54. Childhood-onset of primary Sjögren’s syndrome: phenotypic characterization at diagnosis of 158 children. Ramos-Casals M, Acar-Denizli N, Vissink A, Brito-Zerón P, Li X, Carubbi F, Priori R, Toplak N, Baldini C, Faugier-Fuentes E, Kruize AA, Mandl T, Tomiita M, Gandolfo S, Hashimoto K, Hernandez-Molina G, Hofauer B, Mendieta-Zerón S, Rasmussen A, Sandhya P, Sene D, Trevisani VFM, Isenberg D, Sundberg E, Pasoto SG, Sebastian A, Suzuki Y, Retamozo S, Xu B, Giacomelli R, Gattamelata A, Bizjak M, Bombardieri S, Loor-Chavez RE, Hinrichs A, Olsson P, Bootsma H, Lieberman SM; Sjogren Big Data Consortium*.Rheumatology (Oxford). 2021 Oct 2;60(10):4558-4567. doi: 10.1093/rheumatology/keab032.PMID: 33493333
  55. Stumbles in Sjögren’s syndrome drug development: where to look for the next big leap? Verstappen GM, Kroese FGM, Bootsma H.Expert Rev Clin Immunol. 2020 Nov;16(11):1043-1045. doi: 10.1080/1744666X.2021.1831915. Epub 2020 Nov 16.PMID: 33196342
  56. Current insights into the relationship between the gut microbiome and Sjögren’s syndrome. van der Meulen TA, Kroese FGM, Bootsma H, Spijkervet FKL, Vissink A.Microb Cell Fact. 2020 Nov 13;19(1):210. doi: 10.1186/s12934-020-01471-5.PMID: 33187522
  57. Systemic phenotype related to primary Sjögren’s syndrome in 279 patients carrying isolated anti-La/SSB antibodies. Acar-Denizli N, Horváth IF, Mandl T, Priori R, Vissink A, Hernandez-Molina G, Armagan B, Praprotnik S, Sebastian A, Bartoloni E, Rischmueller M, Pasoto SG, Nordmark G, Nakamura H, Fernandes Moça Trevisani V, Retamozo S, Carsons SE, Maure-Noia B, Sánchez-Berná I, López-Dupla M, Fonseca-Aizpuru E, Melchor Díaz S, Vázquez M, Díaz Cuiza PE, de Miguel Campo B, Ng WF, Rasmussen A, Dong X, Li X, Baldini C, Seror R, Gottenberg JE, Kruize AA, Sandhya P, Gandolfo S, Kwok SK, Kvarnstrom M, Solans R, Sene D, Suzuki Y, Isenberg DA, Valim V, Hofauer B, Giacomelli R, Devauchelle-Pensec V, Atzeni F, Gheita TA, Morel J, Izzo R, Kalyoncu U, Szántó A, Olsson P, Bootsma H, Ramos-Casals M, Kostov B, Brito-Zerón P; Sjögren Big Data Consortium.Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):85-94. Epub 2020 Oct 22.PMID: 33095152  
  58. Ten years of the ESSDAI: is it fit for purpose? de Wolff L, Arends S, van Nimwegen JF, Bootsma H.Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):283-290. Epub 2020 Oct 23.PMID: 33095151  Review.
  59. Blocking T cell co-stimulation in primary Sjogren’s syndrome: rationale, clinical efficacy and modulation of peripheral and salivary gland biomarkers. Pontarini E, Verstappen GM, Grigoriadou S, Kroese FGM, Bootsma H, Bombardieri M.Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):222-227. Epub 2020 Oct 23.PMID: 33095146  Review.
  60. Role of interaction between B cells and epithelial cells in pSS. Pringle S, Verstappen GM, Bootsma H, Kroese FGM.Ann Rheum Dis. 2022 Dec;81(12):e260. doi: 10.1136/annrheumdis-2020-219079. Epub 2020 Oct 15.PMID: 33060075
  61. Recent insights in the potential role of imaging modalities for diagnosing patients with primary Sjögren’s syndrome. Mossel E, Arends S, Bootsma H.Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):310-314. Epub 2020 Sep 22.PMID: 33025898  Review.
  62. Autoimmune congenital heart block and primary Sjögren’s syndrome: characterisation and outcomes of 49 cases. Brito-Zerón P, Pasoto SG, Robles-Marhuenda A, Mandl T, Vissink A, Armagan B, Praprotnik S, Nocturne G, Sebastian A, Fernandes Moça Trevisani V, Retamozo S, Acar-Denizli N, Wiland P, Sisó-Almirall A, Bootsma H, Mariette X, Ramos-Casals M, Kostov B; Sjögren Big Data Consortium.Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):95-102. Epub 2020 Sep 30.PMID: 33025893
  63. 10-year follow-up of patients with rheumatoid arthritis and secondary Sjögren’s syndrome or sicca symptoms in daily clinical practice. Moerman RV, Arends S, Mossel E, Kroese FGM, Vissink A, Bootsma H.Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):64-72. Epub 2020 Sep 23.PMID: 33025888
  64. Checkpoint inhibition-induced sicca: a type II interferonopathy? Pringle S, Wang X, Vissink A, Bootsma H, Kroese FGM.Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):253-260. Epub 2020 Sep 22.PMID: 33025881  Review.
  65. Clinical Phenotyping of Primary Sjögren Syndrome Patients Using Salivary Gland Ultrasonography: Data From the RESULT Cohort.Mossel E, van Nimwegen JF, Stel AJ, Wijnsma RF, Delli K, van Zuiden GS, Olie L, Vehof J, Los LI, Vissink A, Kroese FGM, Arends S, Bootsma H.J Rheumatol. 2021 May;48(5):717-727. doi: 10.3899/jrheum.200482. Epub 2020 Oct 1.PMID: 33004530
  66. Repertoire Analysis of B-Cells Located in Striated Ducts of Salivary Glands of Patients With Sjögren’s Syndrome. Visser A, Verstappen GM, van der Vegt B, Vissink A, Bende RJ, Bootsma H, Bos NA, Kroese FGM.Front Immunol. 2020 Jul 14;11:1486. doi: 10.3389/fimmu.2020.01486. eCollection 2020.PMID: 32760405
  67. Microbiome in Sjögren’s syndrome: here we are. van der Meulen TA, Vissink A, Bootsma H, Spijkervet FKL, Kroese FGM.Ann Rheum Dis. 2022 Jul;81(7):e114. doi: 10.1136/annrheumdis-2020-218213. Epub 2020 Jul 22.PMID: 32699041
  68. Autoantigen TRIM21/Ro52 is expressed on the surface of antigen-presenting cells and its enhanced expression in Sjögren’s syndrome is associated with B cell hyperactivity and type I interferon activity. Hillen MR, Urso K, Koppe E, Lopes AP, Blokland SLM, Pandit A, Slocombe T, van Maurik A, van Roon JAG, Radstake TRDJ.RMD Open. 2020 Jun;6(2):e001184. doi: 10.1136/rmdopen-2020-001184.PMID: 32540951
  69. Gene expression profiling of epithelium-associated FcRL4+ B cells in primary Sjögren’s syndrome reveals a pathogenic signature. Verstappen GM, Ice JA, Bootsma H, Pringle S, Haacke EA, de Lange K, van der Vries GB, Hickey P, Vissink A, Spijkervet FKL, Lessard CJ, Kroese FGM.J Autoimmun. 2020 May;109:102439. doi: 10.1016/j.jaut.2020.102439. Epub 2020 Mar 20.PMID: 32201227
  70. Progenitor cell niche senescence reflects pathology of the parotid salivary gland in primary Sjögren’s syndrome. Wang X, Bootsma H, Terpstra J, Vissink A, van der Vegt B, Spijkervet FKL, Kroese FGM, Pringle S.Rheumatology (Oxford). 2020 Oct 1;59(10):3003-3013. doi: 10.1093/rheumatology/keaa012.PMID: 32159757
  71. Vaginal dryness in primary Sjögren’s syndrome: a histopathological case-control study. van Nimwegen JF, van der Tuuk K, Liefers SC, Verstappen GM, Visser A, Wijnsma RF, Vissink A, Hollema H, Mourits MJE, Bootsma H, Kroese FGM.Rheumatology (Oxford). 2020 Oct 1;59(10):2806-2815. doi: 10.1093/rheumatology/keaa017.PMID: 32044981
  72. Bcl6 for identification of germinal centres in salivary gland biopsies in primary Sjögren’s syndrome. Nakshbandi U, Haacke EA, Bootsma H, Vissink A, Spijkervet FKL, van der Vegt B, Kroese FGM.Oral Dis. 2020 Apr;26(3):707-710. doi: 10.1111/odi.13276. Epub 2020 Jan 28.PMID: 31912593
  73. Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren’s syndrome. Brito-Zerón P, Acar-Denizli N, Ng WF, Horváth IF, Rasmussen A, Seror R, Li X, Baldini C, Gottenberg JE, Danda D, Quartuccio L, Priori R, Hernandez-Molina G, Armagan B, Kruize AA, Kwok SK, Kvarnstrom M, Praprotnik S, Sene D, Gerli R, Solans R, Rischmueller M, Mandl T, Suzuki Y, Isenberg D, Valim V, Wiland P, Nordmark G, Fraile G, Bootsma H, Nakamura H, Giacomelli R, Devauchelle-Pensec V, Hofauer B, Bombardieri M, Trevisani VFM, Hammenfors D, Pasoto SG, Retamozo S, Gheita TA, Atzeni F, Morel J, Vollenweider C, Zeher M, Sivils K, Xu B, Bombardieri S, Sandhya P, De Vita S, Minniti A, Sánchez-Guerrero J, Kilic L, van der Heijden E, Park SH, Wahren-Herlenius M, Mariette X, Ramos-Casals M; Sjögren Big Data Consortium.Rheumatology (Oxford). 2020 Sep 1;59(9):2350-2359. doi: 10.1093/rheumatology/kez578.PMID: 31873754
  74. Decreased circulating CXCR3 + CCR9+T helper cells are associated with elevated levels of their ligands CXCL10 and CCL25 in the salivary gland of patients with Sjogren’s syndrome to facilitate their concerted migration. Blokland SLM, Kislat A, Homey B, Smithson GM, Kruize AA, Radstake TRDJ, van Roon JAG.Scand J Immunol. 2020 Mar;91(3):e12852. doi: 10.1111/sji.12852. Epub 2019 Dec 13.PMID: 31733111
  75. Plasmacytoid DCs From Patients With Sjögren’s Syndrome Are Transcriptionally Primed for Enhanced Pro-inflammatory Cytokine Production. Hillen MR, Pandit A, Blokland SLM, Hartgring SAY, Bekker CPJ, van der Heijden EHM, Servaas NH, Rossato M, Kruize AA, van Roon JAG, Radstake TRDJ.Front Immunol. 2019 Sep 4;10:2096. doi: 10.3389/fimmu.2019.02096. eCollection 2019.PMID: 31552042
  76. Cytometry by time of flight identifies distinct signatures in patients with systemic sclerosis, systemic lupus erythematosus and Sjögrens syndrome. van der Kroef M, van den Hoogen LL, Mertens JS, Blokland SLM, Haskett S, Devaprasad A, Carvalheiro T, Chouri E, Vazirpanah N, Cossu M, Wichers CGK, Silva-Cardoso SC, Affandi AJ, Bekker CPJ, Lopes AP, Hillen MR, Bonte-Mineur F, Kok MR, Beretta L, Rossato M, Mingueneau M, van Roon JAG, Radstake TRDJ.Eur J Immunol. 2020 Jan;50(1):119-129. doi: 10.1002/eji.201948129. Epub 2019 Sep 11.PMID: 31424086
  77. Epigenetically quantified immune cells in salivary glands of Sjogren’s syndrome patients: a novel tool that detects robust correlations of T follicular helper cells with immunopathology. Blokland SLM, van Vliet-Moret FM, Hillen MR, Pandit A, Goldschmeding R, Kruize AA, Bouma G, van Maurik A, Olek S, Hoffmueller U, van Roon JAG, Radstake TRDJ.Rheumatology (Oxford). 2020 Feb 1;59(2):335-343. doi: 10.1093/rheumatology/kez268.PMID: 31325310
  78. MicroRNA-130a Contributes to Type-2 Classical DC-activation in Sjögren’s Syndrome by Targeting Mitogen- and Stress-Activated Protein Kinase-1. Lopes AP, van Roon JAG, Blokland SLM, Wang M, Chouri E, Hartgring SAY, van der Wurff-Jacobs KMG, Kruize AA, Burgering BMT, Rossato M, Radstake TRDJ, Hillen MR.Front Immunol. 2019 Jun 20;10:1335. doi: 10.3389/fimmu.2019.01335. eCollection 2019.PMID: 31281310
  79. Incorporation of Salivary Gland Ultrasonography Into the American College of Rheumatology/European League Against Rheumatism Criteria for Primary Sjögren’s Syndrome. van Nimwegen JF, Mossel E, Delli K, van Ginkel MS, Stel AJ, Kroese FGM, Spijkervet FKL, Vissink A, Arends S, Bootsma H.Arthritis Care Res (Hoboken). 2020 Apr;72(4):583-590. doi: 10.1002/acr.24017.PMID: 31254454
  80. Increased expression of Fas on group 2 and 3 innate lymphoid cells is associated with an interferon signature in systemic lupus erythematosus and Sjögren’s syndrome. Blokland SLM, van den Hoogen LL, Leijten EFA, Hartgring SAY, Fritsch R, Kruize AA, van Roon JAG, Radstake TRDJ.Rheumatology (Oxford). 2019 Oct 1;58(10):1740-1745. doi: 10.1093/rheumatology/kez116.PMID: 31220315
  81. Small-molecule inhibitors and the salivary gland epithelium in Sjögren’s syndrome. Pringle S, Wang X, Bootsma H, Spijkervet FKL, Vissink A, Kroese FGM.Expert Opin Investig Drugs. 2019 Jul;28(7):605-616. doi: 10.1080/13543784.2019.1631796. Epub 2019 Jun 16.PMID: 31203680 Review.
  82. Additive immunosuppressive effect of leflunomide and hydroxychloroquine supports rationale for combination therapy for Sjögren’s syndrome. van der Heijden EH, Hartgring SA, Kruize AA, Radstake TR, van Roon JA.Expert Rev Clin Immunol. 2019 Jul;15(7):801-808. doi: 10.1080/1744666X.2019.1624527. Epub 2019 Jun 13.PMID: 31192747 Clinical Trial.
  83. Dysregulated miRNome of plasmacytoid dendritic cells from patients with Sjögren’s syndrome is associated with processes at the centre of their function. Hillen MR, Chouri E, Wang M, Blokland SLM, Hartgring SAY, Concepcion AN, Kruize AA, Burgering BMT, Rossato M, van Roon JAG, Radstake TRDJ.Rheumatology (Oxford). 2019 Dec 1;58(12):2305-2314. doi: 10.1093/rheumatology/kez195.PMID: 31131409
  84. Presence of intraepithelial B-lymphocytes is associated with the formation of lymphoepithelial lesions in salivary glands of primary Sjögren’s syndrome patients. van Ginkel MS, Haacke EA, Bootsma H, Arends S, van Nimwegen JF, Verstappen GM, Spijkervet FKL, Vissink A, van der Vegt B, Kroese FGM.Clin Exp Rheumatol. 2019 May-Jun;37 Suppl 118(3):42-48. Epub 2019 Apr 29.PMID: 31074726
  85. Fatigue in Sjögren’s Syndrome: A Search for Biomarkers and Treatment Targets. Bodewes ILA, van der Spek PJ, Leon LG, Wijkhuijs AJM, van Helden-Meeuwsen CG, Tas L, Schreurs MWJ, van Daele PLA, Katsikis PD, Versnel MA.Front Immunol. 2019 Feb 26;10:312. doi: 10.3389/fimmu.2019.00312. eCollection 2019.PMID: 30863411
  86. Salivary gland secretome: a novel tool towards molecular stratification of patients with primary Sjögren’s syndrome and non-autoimmune sicca.
  87. Blokland SLM, Hillen MR, van Vliet-Moret FM, Bikker A, de Jager W, Pandit A, Kruize AA, Radstake TRDJ, van Roon JAG.RMD Open. 2019 Jan 11;5(1):e000772. doi: 10.1136/rmdopen-2018-000772. eCollection 2019.PMID: 30713719
  88. Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjogren’s syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology?
  89. Blokland SLM, Hillen MR, Wichers CGK, Zimmermann M, Kruize AA, Radstake TRDJ, Broen JCA, van Roon JAG.RMD Open. 2019 Jan 11;5(1):e000701. doi: 10.1136/rmdopen-2018-000701. eCollection 2019.PMID: 30713717
  90. World Workshop on Oral Medicine VII: Biomarkers predicting lymphoma in the salivary glands of patients with Sjögren’s syndrome-A systematic review. Delli K, Villa A, Farah CS, Celentano A, Ojeda D, Peterson DE, Jensen SB, Glurich I, Vissink A.Oral Dis. 2019 Jun;25 Suppl 1:49-63. doi: 10.1111/odi.13041.PMID: 30663837
  91. Galectin-9 reflects the interferon signature and correlates with disease activity in systemic autoimmune diseases. Response to: ‘Biomarkers: to be or not to be’ by Yavuz and Rönnblom. van den Hoogen LL, van der Heijden EHM, Hillen MR, Mertens JS, Fritsch-Stork RDE, Radstake TRDJ, van Roon JAG.Ann Rheum Dis. 2020 Jan;79(1):e9. doi: 10.1136/annrheumdis-2018-214651. Epub 2018 Dec 8.PMID: 30530825
  92. Normal vaginal microbiome in women with primary Sjögren’s syndrome-associated vaginal dryness. van der Meulen TA, van Nimwegen JF, Harmsen HJM, Liefers SC, van der Tuuk K, Kroese FGM, Mourits MJE, Vissink A, Bootsma H.Ann Rheum Dis. 2019 May;78(5):707-709. doi: 10.1136/annrheumdis-2018-214404. Epub 2018 Nov 28.PMID: 30487150
  93. d gut, but distinct oral microbiota composition in primary Sjögren’s syndrome and systemic lupus erythematosus. van der Meulen TA, Harmsen HJM, Vila AV, Kurilshikov A, Liefers SC, Zhernakova A, Fu J, Wijmenga C, Weersma RK, de Leeuw K, Bootsma H, Spijkervet FKL, Vissink A, Kroese FGM.J Autoimmun. 2019 Feb;97:77-87. doi: 10.1016/j.jaut.2018.10.009. Epub 2018 Nov 9.PMID: 30416033
  94. Germinal Centers in Diagnostic Biopsies of Patients With Primary Sjögren’s Syndrome Are Not a Risk Factor for Non-Hodgkin’s Lymphoma but a Reflection of High Disease Activity: Comment on the Article by Sène et al. Haacke EA, van der Vegt B, Vissink A, Spijkervet FKL, Bootsma H, Kroese FGM.Arthritis Rheumatol. 2019 Jan;71(1):170-171. doi: 10.1002/art.40715. Epub 2018 Nov 24.PMID: 30178631
  95. Patient-reported change of sensibility and pain after parotid and labial gland biopsy applied for primary Sjögren’s syndrome diagnostics: one-year follow-up study. Delli K, Dagal EF, Bootsma H, Vissink A, Spijkervet FKL.Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):173-176. Epub 2018 Jul 25.PMID: 30156543
  96. Dysbiosis of the buccal mucosa microbiome in primary Sjögren’s syndrome patients. van der Meulen TA, Harmsen HJM, Bootsma H, Liefers SC, Vich Vila A, Zhernakova A, Fu J, Wijmenga C, Spijkervet FKL, Kroese FGM, Vissink A.Rheumatology (Oxford). 2018 Dec 1;57(12):2225-2234. doi: 10.1093/rheumatology/key215.PMID: 30060225
  97. Salivary Gland Stem Cells Age Prematurely in Primary Sjögren’s Syndrome. Pringle S, Wang X, Verstappen GMPJ, Terpstra JH, Zhang CK, He A, Patel V, Jones RE, Baird DM, Spijkervet FKL, Vissink A, Bootsma H, Coppes RP, Kroese FGM.Arthritis Rheumatol. 2019 Jan;71(1):133-142. doi: 10.1002/art.40659.PMID: 29984480
  98. Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sjögren’s syndrome. Verstappen GM, Moerman RV, van Nimwegen JF, van Ginkel MS, Bijzet J, Mossel E, Vissink A, Hazenberg BPC, Arends S, Kroese FGM, Bootsma H.Rheumatology (Oxford). 2018 Oct 1;57(10):1812-1821. doi: 10.1093/rheumatology/key180.PMID: 29982712
  99. Autoantibodies to Cytosolic 5′-Nucleotidase 1A in Primary Sjögren’s Syndrome and Systemic Lupus Erythematosus. Rietveld A, van den Hoogen LL, Bizzaro N, Blokland SLM, Dähnrich C, Gottenberg JE, Houen G, Johannsen N, Mandl T, Meyer A, Nielsen CT, Olsson P, van Roon J, Schlumberger W, van Engelen BGM, Saris CGJ, Pruijn GJM.Front Immunol. 2018 Jun 5;9:1200. doi: 10.3389/fimmu.2018.01200. eCollection 2018.PMID: 29922285
  100. TBK1: A key regulator and potential treatment target for interferon positive Sjögren’s syndrome, systemic lupus erythematosus and systemic sclerosis. Bodewes ILA, Huijser E, van Helden-Meeuwsen CG, Tas L, Huizinga R, Dalm VASH, van Hagen PM, Groot N, Kamphuis S, van Daele PLA, Versnel MA.J Autoimmun. 2018 Jul;91:97-102. doi: 10.1016/j.jaut.2018.02.001. Epub 2018 Apr 16.PMID: 29673738
  101. Acquisition of N-Glycosylation Sites in Immunoglobulin Heavy Chain Genes During Local Expansion in Parotid Salivary Glands of Primary Sjögren Patients. Visser A, Doorenspleet ME, de Vries N, Spijkervet FKL, Vissink A, Bende RJ, Bootsma H, Kroese FGM, Bos NA.Front Immunol. 2018 Mar 12;9:491. doi: 10.3389/fimmu.2018.00491. eCollection 2018.PMID: 29662487
  102. Reduced salivary secretion contributes more to changes in the oral microbiome of patients with primary Sjögren’s syndrome than underlying disease. van der Meulen TA, Harmsen HJM, Bootsma H, Liefers SC, Vich Vila A, Zhernakova A, Weersma RK, Spijkervet FKL, Kroese FGM, Vissink A.Ann Rheum Dis. 2018 Oct;77(10):1542-1544. doi: 10.1136/annrheumdis-2018-213026. Epub 2018 Mar 23.PMID: 29572289
  103. Is the T Follicular Regulatory:Follicular Helper T Cell Ratio in Blood a Biomarker for Ectopic Lymphoid Structure Formation in Sjogren’s Syndrome? Comment on the Article by Fonseca et al. Verstappen GM, Nakshbandi U, Mossel E, Haacke EA, van der Vegt B, Vissink A, Bootsma H, Kroese FGM.Arthritis Rheumatol. 2018 Aug;70(8):1354-1355. doi: 10.1002/art.40488. Epub 2018 Jun 22.PMID: 29534333
  104. Can ultrasound of the major salivary glands assess histopathological changes induced by treatment with rituximab in primary Sjögren’s syndrome? Mossel E, Delli K, Arends S, Haacke EA, van der Vegt B, van Nimwegen JF, Stel AJ, Spijkervet FKL, Vissink A, Kroese FGM, Bootsma H.Ann Rheum Dis. 2019 Apr;78(4):e27. doi: 10.1136/annrheumdis-2018-213332. Epub 2018 Mar 9.PMID: 29523521
  105. Systemic interferon type I and type II signatures in primary Sjögren’s syndrome reveal differences in biological disease activity. Bodewes ILA, Al-Ali S, van Helden-Meeuwsen CG, Maria NI, Tarn J, Lendrem DW, Schreurs MWJ, Steenwijk EC, van Daele PLA, Both T, Bowman SJ, Griffiths B, Ng WF; UK Primary Sjögren’s Syndrome registry; Versnel MA.Rheumatology (Oxford). 2018 May 1;57(5):921-930. doi: 10.1093/rheumatology/kex490.PMID: 29474655
  106. Circulating small non-coding RNAs reflect IFN status and B cell hyperactivity in patients with primary Sjögren’s syndrome. Lopes AP, Hillen MR, Chouri E, Blokland SLM, Bekker CPJ, Kruize AA, Rossato M, van Roon JAG, Radstake TRDJ.PLoS One. 2018 Feb 15;13(2):e0193157. doi: 10.1371/journal.pone.0193157. eCollection 2018.PMID: 29447268
  107. Validation of the ACR-EULAR criteria for primary Sjögren’s syndrome in a Dutch prospective diagnostic cohort. van Nimwegen JF, van Ginkel MS, Arends S, Haacke EA, van der Vegt B, Sillevis Smitt-Kamminga N, Spijkervet FKL, Kroese FGM, Stel AJ, Brouwer E, Vissink A, Bootsma H.Rheumatology (Oxford). 2018 May 1;57(5):818-825. doi: 10.1093/rheumatology/kex495.PMID: 29444331
  108. Scoring hypoechogenic areas in one parotid and one submandibular gland increases feasibility of ultrasound in primary Sjögren’s syndrome. Mossel E, Arends S, van Nimwegen JF, Delli K, Stel AJ, Kroese FGM, Spijkervet FKL, Vissink A, Bootsma H; EULAR US-pSS study group.Ann Rheum Dis. 2018 Apr;77(4):556-562. doi: 10.1136/annrheumdis-2017-211992. Epub 2017 Dec 12.PMID: 29233833
  109. Th17 cells in primary Sjögren’s syndrome: Pathogenicity and plasticity. Verstappen GM, Corneth OBJ, Bootsma H, Kroese FGM.J Autoimmun. 2018 Feb;87:16-25. doi: 10.1016/j.jaut.2017.11.003. Epub 2017 Nov 27.PMID: 29191572  Review.
  110. Ultrasound of the Major Salivary Glands is a Reliable Imaging Technique in Patients with Clinically Suspected Primary Sjögren’s Syndrome. Delli K, Arends S, van Nimwegen JF, Dijkstra PU, Stel AJ, Spijkervet FKL, Bootsma H, Vissink A.Ultraschall Med. 2018 Jun;39(3):328-333. doi: 10.1055/s-0043-104631. Epub 2017 Oct 25.PMID: 29069669 English.
  111. The parotid gland connection: ultrasound and biopsies in primary Sjögren’s syndrome. Mossel E, Delli K, van Nimwegen JF, Stel AJ, Haacke EA, Kroese FGM, Spijkervet FKL, Vissink A, Arends S, Bootsma H.Ann Rheum Dis. 2018 Jul;77(7):e38. doi: 10.1136/annrheumdis-2017-212331. Epub 2017 Sep 29.PMID: 28970210
  112. Standardisation of the detection of germinal centres in salivary gland biopsies of patients with primary Sjögren’s syndrome is needed to assess their clinical relevance. Haacke EA, van der Vegt B, Vissink A, Spijkervet FKL, Bootsma H, Kroese FGM.Ann Rheum Dis. 2018 Jun;77(6):e32. doi: 10.1136/annrheumdis-2017-212164. Epub 2017 Sep 22.PMID: 28939628
  113. Ultrasonography of major salivary glands compared with parotid and labial gland biopsy and classification criteria in patients with clinically suspected primary Sjögren’s syndrome. Mossel E, Delli K, van Nimwegen JF, Stel AJ, Kroese FGM, Spijkervet FKL, Vissink A, Arends S, Bootsma H; EULAR US-pSS Study Group.Ann Rheum Dis. 2017 Nov;76(11):1883-1889. doi: 10.1136/annrheumdis-2017-211250. Epub 2017 Jul 28.PMID: 28754802
  114. Germinal centres in diagnostic labial gland biopsies of patients with primary Sjögren’s syndrome are not predictive for parotid MALT lymphoma development. Haacke EA, van der Vegt B, Vissink A, Spijkervet FKL, Bootsma H, Kroese FGM.Ann Rheum Dis. 2017 Oct;76(10):1781-1784. doi: 10.1136/annrheumdis-2017-211290. Epub 2017 Jul 14.PMID: 28710097
  115. Increased CCL25 and T Helper Cells Expressing CCR9 in the Salivary Glands of Patients With Primary Sjogren’s Syndrome: Potential New Axis in Lymphoid Neogenesis. Blokland SLM, Hillen MR, Kruize AA, Meller S, Homey B, Smithson GM, Radstake TRDJ, van Roon JAG.Arthritis Rheumatol. 2017 Oct;69(10):2038-2051. doi: 10.1002/art.40182. Epub 2017 Aug 29.PMID: 28622456
  116. Attenuation of Follicular Helper T Cell-Dependent B Cell Hyperactivity by Abatacept Treatment in Primary Sjogren’s Syndrome. Verstappen GM, Meiners PM, Corneth OBJ, Visser A, Arends S, Abdulahad WH, Hendriks RW, Vissink A, Kroese FGM, Bootsma H.Arthritis Rheumatol. 2017 Sep;69(9):1850-1861. doi: 10.1002/art.40165. Epub 2017 Aug 13.PMID: 28564491 Clinical Trial.
  117. The value of rituximab treatment in primary Sjögren’s syndrome. Verstappen GM, van Nimwegen JF, Vissink A, Kroese FGM, Bootsma H.Clin Immunol. 2017 Sep;182:62-71. doi: 10.1016/j.clim.2017.05.002. Epub 2017 May 3.PMID: 28478105  Review.
  118. FcRL4+ B-cells in salivary glands of primary Sjögren’s syndrome patients. Haacke EA, Bootsma H, Spijkervet FKL, Visser A, Vissink A, Kluin PM, Kroese FGM.J Autoimmun. 2017 Jul;81:90-98. doi: 10.1016/j.jaut.2017.03.012. Epub 2017 Apr 6.PMID: 28390747
  119. Editorial: Rituximab in the Treatment of Sjögren’s Syndrome: Is It the Right or Wrong Drug? Bootsma H, Kroese FGM, Vissink A.Arthritis Rheumatol. 2017 Jul;69(7):1346-1349. doi: 10.1002/art.40095. Epub 2017 Jun 7.PMID: 28296253
  120. Enhanced Bruton’s Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease. Corneth OBJ, Verstappen GMP, Paulissen SMJ, de Bruijn MJW, Rip J, Lukkes M, van Hamburg JP, Lubberts E, Bootsma H, Kroese FGM, Hendriks RW.Arthritis Rheumatol. 2017 Jun;69(6):1313-1324. doi: 10.1002/art.40059. Epub 2017 May 10.PMID: 28141917
  121. Detailed Analysis of the Articular Domain in Patients with Primary Sjögren Syndrome. Moerman RV, Arends S, Meiners PM, Vissink A, Spijkervet FK, Kroese FG, Brouwer E, Bootsma H.J Rheumatol. 2017 Mar;44(3):292-296. doi: 10.3899/jrheum.160459. Epub 2017 Jan 15.PMID: 28089983
  122. B Cell Depletion Therapy Normalizes Circulating Follicular Th Cells in Primary Sjögren Syndrome. Verstappen GM, Kroese FG, Meiners PM, Corneth OB, Huitema MG, Haacke EA, van der Vegt B, Arends S, Vissink A, Bootsma H, Abdulahad WH.J Rheumatol. 2017 Jan;44(1):49-58. doi: 10.3899/jrheum.160313. Epub 2016 Nov 15.PMID: 28042126

 

Spreekkamerkaarten

Klik hier om de spreekkamerkaart voor Sjögren te bekijken (NVSP.nl)